Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

CANCER RISK IN PEDIATRIC-ONSET RHEUMATIC DISEASE

Award Number: R03CA149970
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/19/2011
PERIOD OF PERFORMANCE END DATE: 08/31/2013

Group Awards By:

View Award Description

CANCER RISK IN PEDIATRIC-ONSET RHEUMATIC DISEASE - DESCRIPTION (provided by applicant): The association of cancer with autoimmune disease has been under study for years. In adults, there is evidence of increased cancer risk in several autoimmune rheumatic diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). There are essentially no data on malignancy occurrence in pediatric-onset rheumatic diseases such as juvenile SLE and juvenile idiopathic arthritis (JIA, which includes the pediatric equivalent of RA). Extrapolations from adult-onset populations are inappropriate, given clinical differences between these diseases across age groups. Power issues necessitate the use of multi-centre efforts in order to definitely establish the risk in juvenile-onset populations, relative to age and sex matched general population cancer rates. The study objectives are to examine cancer incidence in two multi-centre pediatric rheumatic disease cohorts; one with pediatric-onset SLE and one with JIA, and to determine if this is increased compared to age, sex, and calendar-year general population cancer incidence rates. All patients will be linked to regional tumor registries to determine cancer occurrence over the observation interval. The person-years of follow-up for each subject will be calculated from the date first seen at the respective clinic, and the first of three possible events: death, cancer, or the end of the study interval. Standardized incidence ratios (SIRs) will be calculated as the ratio of observed to expected cancers. Cancers expected will be determined by multiplying person-years in the cohort by the geographically matched age, sex, and calendar year-specific cancer rates, and summing over all person-years. This study is important, given that survival in pediatric-onset rheumatic disease has improved in the recent past, and there is increasing interest in the morbidity that these patients suffer, long-term. Given the data that has been demonstrated in SLE and RA of adult onset, malignancy risk is of particular concern to children who are affected by these conditions. The information generated from this study will be of crucial importance not only to clinicians, but also to patients and their families. This work will also set the stage for further evaluations. If an increased risk is demonstrated, the researchers will complete further studies to assess the relative importance of disease activity and medication exposures as risk factors for malignancy development in pediatric-onset SLE and JIA. The collaboration and combined resources represented in this application signifies an unprecedented opportunity.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2012 ( Subtotal = $43,351 )
2012	2012	RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CTR	tgnih07.05	MONTREAL				CAN	Cancer Cause and Prevention Research	001	2	8/6/2012	NON-COMPETING CONTINUATION	$43,351
2012	2011	RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CTR	RI MUHC MGH SITE ROOM S2-214	MONTREAL				CAN	Cancer Cause and Prevention Research	000	1	11/3/2011	NEW	$0
														Subtotal = $43,351

Issue Date FY: 2011 ( Subtotal = $47,322 )
2011	2011	RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CTR	tgnih07.05	MONTREAL				CAN	Cancer Cause and Prevention Research	000	1	9/19/2011	NEW	$47,322
														Subtotal = $47,322

Grand Total All Awards = $90,673

Top

All Categories

About

Search

Reports

Data Submission

Award Information

CANCER RISK IN PEDIATRIC-ONSET RHEUMATIC DISEASE

Award Number: R03CA149970

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/19/2011

PERIOD OF PERFORMANCE END DATE: 08/31/2013

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer